Skip to main content
Clinical Trials/NCT06106230
NCT06106230
Completed
Not Applicable

Bee Venom Phonophoresis on Mild to Moderate Localized Plaque Psoriasis on Knee Joint

MTI University1 site in 1 country100 target enrollmentJanuary 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Plaque Psoriasis
Sponsor
MTI University
Enrollment
100
Locations
1
Primary Endpoint
Neutrophils / Lymphocyte Ratio (Neutrophil-to-Lymphocyte Ratio)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Chronic plaque psoriasis, or psoriasis vulgaris, is a chronic inflammatory skin disease characterized by well demarcated, erythematous, scaly plaques on the extensor surfaces of the body and scalp. The lesions may occasionally itch or sting, and may bleed when injured. Dystrophic nail changes or nail pitting are found in more than one third of people with chronic plaque psoriasis, and psoriatic arthropathy occurs in 1% to more than 10%. The condition waxes and wanes, with wide variations in course and severity among individuals.

Detailed Description

Apitherapy is an alternate therapy that relies on the usage of honeybee products, most importantly bee venom for the treatment of many human diseases. The venom can be introduced into the human body by manual injection or by direct bee stings. Bee venom contains several active molecules such as peptides and enzymes that have advantageous potential in treating inflammation and central nervous system diseases, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. Moreover, bee venom has shown promising benefits against different types of cancer as well as anti-viral activity, even against the challenging human immunodeficiency virus (HIV). Many studies described biological activities of bee venom components and launched preclinical trials to improve the potential use of apitoxin and its constituents as the next generation of drugs. Chronic plaque psoriasis is the most common form of psoriasis, accounting for more than 80% of cases. It is a chronic relapsing and remitting condition that presents as symmetrical, well-demarcated, erythematous thickened plaques with overlying silver scales. Appearance can vary depending on skin colour, ranging from pink on lighter skin to brown, purple, or grey on darker skin. It commonly affects the extensor surfaces (elbows and knees), scalp, trunk, and gluteal fold, but may arise on any part of the body. Plaques may coalesce to involve extensive areas of the skin, especially on the trunk and limbs.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
April 15, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmed Mohamed Ahmed Abd El hady El Fahl,ph.d

lectrurer of physical therapy for general surgery and dermatology

MTI University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Neutrophils / Lymphocyte Ratio (Neutrophil-to-Lymphocyte Ratio)

Time Frame: base line after 12 weeks

Ratio

(ESR) erythrocyte sedimentation rate

Time Frame: base line after 12 weeks

ESR

C-reactive protein (CRP)

Time Frame: base line after 12 weeks

A C-reactive protein (CRP) test measures the level of C-reactive protein in your blood.

Secondary Outcomes

  • Isokinetic machine proprioceptive test(base line after 12 weeks)
  • PASI score(base line after 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials